Biomedical Systems Launches Next Generation eCOA Technology
(St. Louis; March 10, 2015)– Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data. This new electronic patient recorded outcome (ePRO) technology improves patient and investigator user experience, improves patient compliance and expedites study setup by simplifying site tasks and reducing errors.
Biomedical Systems’ electronic clinical outcome assessment (eCOA) technology is used for clinical trials in more than 40 countries for multiple therapeutic areas including respiratory, gastrointestinal, dermatology, oncology and women’s health. Biomedical Systems is the only company providing eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.
“The eCOA market is growing fast, and launching this technology enhances our ability to offer centralized diagnostic services,” said Tim Barrett, chief executive officer at Biomedical Systems. “In 40 years, Biomedical Systems has built a premier global presence based on centralized diagnostic services and logistics excellence. Our eCOA solutions will extend that prompt, reliable global service we’re known for to provide more reliable data while collecting data for primary and secondary endpoints.”
Biomedical Systems’ eCOA technology offers the flexibility, reliability and robustness of the Android operating system. QR code technology is used to reduce investigators’ burden, improve security and, more importantly, ease the data capture process. With this platform, Biomedical Systems focused on patients’ ease of use by providing new features that improve compliance and worldwide reliable data transmission using the latest telecommunication technologies. In addition, Biomedical Systems relies on a strong and proactive project management team that is key to successful eCOA trials.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
